Daniele Pastori1,2, Kazuo Miyazawa1, Yanguang Li1,3, Orsolya Székely1, Farhan Shahid1, Alessio Farcomeni4, Gregory Y H Lip5,6,7. 1. Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 2. Department of Internal Medicine and Medical Specialties, I Clinica Medica, Atherothrombosis Center, Sapienza University of Rome, Rome, Italy. 3. Department of Cardiology, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, China. 4. Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. 5. Institute of Applied Health Research, University of Birmingham, Birmingham, UK. gregory.lip@liverpool.ac.uk. 6. Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK. gregory.lip@liverpool.ac.uk. 7. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. gregory.lip@liverpool.ac.uk.
Abstract
BACKGROUND: Patients with atrial high-rate episodes (AHREs) are at higher risk of thromboembolic events and mortality. The risk of major adverse cardiovascular events (MACE) in these patients is unknown. OBJECTIVE: To investigate the risk of MACE in patients implanted with cardiac implantable electronic devices (CIEDs) developing AHREs METHODS AND RESULTS: We included 852 consecutive patients undergoing CIEDs implantation. Primary outcome was a composite endpoint of MACEs occurring after AHREs ≥ 5 min. AHRE was defined as > 175 bpm and lasting ≥ 5 min. We also performed a subgroup analysis in patients with the longest AHRE lasting ≥ 24 h. Cox regression analysis with time-dependent covariates was used to investigate the relationship between AHREs and MACEs. Mean age was 70.0 ± 13.6 years, and 39.3% were women: 325 patients developed AHREs ≥ 5 min [incidence rate (IR) 13.1% year 95% confidence interval (CI) 11.7-14.6] and 124 patients developed AHREs ≥ 24 h (IR 3.7%/year 95% CI 3.1-4.5). During a median follow-up of 37.0 months (IQR 19.0-64.3, 316,132 patient-years), 152 MACEs occurred (IR 4.85%/year, 95% CI 4.11-5.68). The IR of MACE occurring after AHREs onset was higher in patients developing AHREs ≥ 24 h (IR 1.13%/year) than AHREs ≥ 5 min (IR 0.63%/year, p = 0.030). Multivariable Cox regression analysis showed that AHREs ≥ 5 min (HR 1.788, 95% CI 1.247-2.562, p = 0.002), diabetes (HR 1.909, 95% CI 1.358-2.683, p < 0.001), heart failure (HR 2.203, 95% CI 1.527-3.178, p < 0.001), and coronary artery disease (HR 1.862, 95% CI 1.293-2.681, p = 0.001) were associated to MACE. This association was even stronger for AHREs ≥ 24 h (HR 2.390, 95% CI 1.481-3.857, p < 0.001). CONCLUSIONS: Patients implanted with CIEDs developing AHREs show a significant risk for MACE, which is dependent on AHREs burden. Cardiovascular prevention strategies in this patient population are warranted.
BACKGROUND:Patients with atrial high-rate episodes (AHREs) are at higher risk of thromboembolic events and mortality. The risk of major adverse cardiovascular events (MACE) in these patients is unknown. OBJECTIVE: To investigate the risk of MACE in patients implanted with cardiac implantable electronic devices (CIEDs) developing AHREs METHODS AND RESULTS: We included 852 consecutive patients undergoing CIEDs implantation. Primary outcome was a composite endpoint of MACEs occurring after AHREs ≥ 5 min. AHRE was defined as > 175 bpm and lasting ≥ 5 min. We also performed a subgroup analysis in patients with the longest AHRE lasting ≥ 24 h. Cox regression analysis with time-dependent covariates was used to investigate the relationship between AHREs and MACEs. Mean age was 70.0 ± 13.6 years, and 39.3% were women: 325 patients developed AHREs ≥ 5 min [incidence rate (IR) 13.1% year 95% confidence interval (CI) 11.7-14.6] and 124 patients developed AHREs ≥ 24 h (IR 3.7%/year 95% CI 3.1-4.5). During a median follow-up of 37.0 months (IQR 19.0-64.3, 316,132 patient-years), 152 MACEs occurred (IR 4.85%/year, 95% CI 4.11-5.68). The IR of MACE occurring after AHREs onset was higher in patients developing AHREs ≥ 24 h (IR 1.13%/year) than AHREs ≥ 5 min (IR 0.63%/year, p = 0.030). Multivariable Cox regression analysis showed that AHREs ≥ 5 min (HR 1.788, 95% CI 1.247-2.562, p = 0.002), diabetes (HR 1.909, 95% CI 1.358-2.683, p < 0.001), heart failure (HR 2.203, 95% CI 1.527-3.178, p < 0.001), and coronary artery disease (HR 1.862, 95% CI 1.293-2.681, p = 0.001) were associated to MACE. This association was even stronger for AHREs ≥ 24 h (HR 2.390, 95% CI 1.481-3.857, p < 0.001). CONCLUSIONS:Patients implanted with CIEDs developing AHREs show a significant risk for MACE, which is dependent on AHREs burden. Cardiovascular prevention strategies in this patient population are warranted.
Authors: Christina Ji-Young Lee; Thomas Alexander Gerds; Nicholas Carlson; Anders Nissen Bonde; Gunnar Hilmar Gislason; Morten Lamberts; Jonas Bjerring Olesen; Jannik Langtved Pallisgaard; Morten Lock Hansen; Christian Torp-Pedersen Journal: J Am Coll Cardiol Date: 2018-07-03 Impact factor: 24.094
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Bulent Gorenek; Jeroen Bax; Giuseppe Boriani; Shih-Ann Chen; Nikolaos Dagres; Taya V Glotzer; Jeff S Healey; Carsten W Israel; Gulmira Kudaiberdieva; Lars-Åke Levin; Gregory Y H Lip; David Martin; Ken Okumura; Jesper H Svendsen; Hung-Fat Tse; Giovanni L Botto Journal: Europace Date: 2017-09-01 Impact factor: 5.214
Authors: Jeff S Healey; Stuart J Connolly; Michael R Gold; Carsten W Israel; Isabelle C Van Gelder; Alessandro Capucci; C P Lau; Eric Fain; Sean Yang; Christophe Bailleul; Carlos A Morillo; Mark Carlson; Ellison Themeles; Elizabeth S Kaufman; Stefan H Hohnloser Journal: N Engl J Med Date: 2012-01-12 Impact factor: 91.245
Authors: Gelu Simu; Radu Rosu; Gabriel Cismaru; Mihai Puiu; Gabriel Gusetu; Ioan Minciuna; Sabina Istratoaie; Raluca Tomoaia; Dumitru Zdrenghea; Dana Pop Journal: Cardiovasc J Afr Date: 2021-01-15 Impact factor: 0.802
Authors: Jacopo Francesco Imberti; Alberto Tosetti; Davide Antonio Mei; Anna Maisano; Giuseppe Boriani Journal: Curr Cardiol Rep Date: 2021-05-07 Impact factor: 2.931